Dr. Muggia on Targeted Therapies in Ovarian Cancer

Franco M. Muggia, MD
Published Online: Thursday, November 14, 2013
Franco M. Muggia, MD, Franco M. Muggia, MD, The Anne Murnick Cogan and David H. Cogan Professor of Oncology, NYU Langone Medical Center, discusses the challenge of developing targeted therapies to treat ovarian cancer.

Muggia says drug development in ovarian cancer has not been easy, resulting in a lack of targeted therapies. Physicians rely on a chemotherapy regimen to treat patients with ovarian cancer that eliminates advanced disease about 80-90% of the time. However, Muggia says, the disease eventually comes back.

Muggia says there is a need to improve treatment for ovarian cancer. BRCA and PARP targets have proven to be good targets to develop further.

Online CME Activities
Free CME from PER
Evolving Management Strategies for Triple-Negative Breast Cancer
Community Practice Connections™: Current and Emerging Strategies in the Management of Early Breast Cancer
Cancer Summaries and Commentaries™: Update from Vienna: Advances in the Treatment of Gastrointestinal Cancers
Advances in Targeted Therapy: The Emerging Role of PARP Inhibitors in the Treatment of Cancers
More Reading